BTLA

BTLA
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesBTLA, BTLA1, CD272, B and T lymphocyte associated
External IDsMGI: 2658978 HomoloGene: 52233 GeneCards: BTLA
Orthologs
SpeciesHumanMouse
Entrez

151888

208154

Ensembl

ENSG00000186265

ENSMUSG00000052013

UniProt

Q7Z6A9

Q7TSA3

RefSeq (mRNA)

NM_001085357
NM_181780

NM_001037719
NM_177584

RefSeq (protein)

NP_001078826
NP_861445

NP_001032808
NP_808252

Location (UCSC)Chr 3: 112.46 – 112.5 MbChr 16: 45.22 – 45.25 Mb
PubMed search[1][2]
Wikidata
View/Edit HumanView/Edit Mouse

B- and T-lymphocyte attenuator is a protein that in humans is encoded by the BTLA gene.[3][4] BTLA has also been designated as CD272 (cluster of differentiation 272).

Function

BTLA expression is induced during activation of T cells, and BTLA remains expressed on Th1 cells but not Th2 cells. Like PD1 and CTLA4, BTLA interacts with a B7 homolog, B7H4.[4] However, unlike PD-1 and CTLA-4, BTLA displays T-Cell inhibition via interaction with tumor necrosis family receptors (TNF-R), not just the B7 family of cell surface receptors. BTLA is a ligand for tumour necrosis factor (receptor) superfamily, member 14 (TNFRSF14), also known as herpes virus entry mediator (HVEM). BTLA-HVEM complexes negatively regulate T-cell immune responses.

Clinical significance

BTLA activation inhibits the function of human CD8+ cancer-specific T cells.[5]

References

  1. "Human PubMed Reference:".
  2. "Mouse PubMed Reference:".
  3. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM (Jun 2003). "BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1". Nat Immunol. 4 (7): 670–9. PMID 12796776. doi:10.1038/ni944.
  4. 1 2 "Entrez Gene: BTLA B and T lymphocyte associated".
  5. Derré L, Rivals J-P, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Olive D, Speiser DE (2009). "BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination". J Clin Invest. 120 (1): 157–67. PMC 2799219Freely accessible. PMID 20038811. doi:10.1172/JCI40070. Lay summary Genetic Engineering & Biotechnology News.

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.